• Home Blog Tag Chronic inflammatory demyelinating polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy

pharma-news-for-alnylam-bms-daichii-sankyo-vertex

Jun 25, 2024

Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval

Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments.

Apr 13, 2018

Chronic Inflammatory Demyelinating Polyneuropathy – lack of Effective treatment

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper